{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T23:13:49Z","timestamp":1793056429148,"version":"4.5.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T00:00:00Z","timestamp":1777939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T00:00:00Z","timestamp":1777939200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Osteoporos Rep"],"DOI":"10.1007\/s11914-026-00967-0","type":"journal-article","created":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T03:11:07Z","timestamp":1777950667000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Sequential Versus Step-Therapy Approaches for Osteoporosis Management in Orthopedic Subspecialties"],"prefix":"10.1007","volume":"24","author":[{"given":"Samer G.","family":"Salman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohan","family":"Phadke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Burnett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Walsh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,5]]},"reference":[{"issue":"11","key":"967_CR1","doi-asserted-by":"publisher","first-page":"2520","DOI":"10.1002\/jbmr.2269","volume":"29","author":"NC Wright","year":"2014","unstructured":"Wright NC, Looker AC, Saag KG, Curtis JR, Delzell ES, Randall S, et al. The recent prevalence of osteoporosis and low bone mass in the United States based on bone mineral density at the femoral neck or lumbar spine. J Bone Min Res. 2014;29(11):2520\u20136. https:\/\/doi.org\/10.1002\/jbmr.2269.","journal-title":"J Bone Min Res"},{"issue":"3","key":"967_CR2","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1359\/jbmr.061113","volume":"22","author":"R Burge","year":"2007","unstructured":"Burge R, Dawson-Hughes B, Solomon DH, Wong JB, King A, Tosteson A. Incidence and economic burden of osteoporosis-related fractures in the United States, 2005\u20132025. J Bone Min Res. 2007;22(3):465\u201375. https:\/\/doi.org\/10.1359\/jbmr.061113.","journal-title":"J Bone Min Res"},{"issue":"9","key":"967_CR3","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1002\/jbmr.2202","volume":"29","author":"DH Solomon","year":"2014","unstructured":"Solomon DH, Johnston SS, Boytsov NN, McMorrow D, Lane JM, Krohn KD. Osteoporosis medication use after hip fracture in U.S. patients between 2002 and 2011. J Bone Min Res. 2014;29(9):1929\u201337. https:\/\/doi.org\/10.1002\/jbmr.2202.","journal-title":"J Bone Min Res"},{"issue":"1","key":"967_CR4","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s11914-025-00909-2","volume":"23","author":"MR McClung","year":"2025","unstructured":"McClung MR. Sequential and long-term therapy for osteoporosis. Curr Osteoporos Rep. 2025;23(1):15. https:\/\/doi.org\/10.1007\/s11914-025-00909-2.","journal-title":"Curr Osteoporos Rep"},{"issue":"Suppl 1","key":"967_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4158\/GL-2020-0524SUPPL","volume":"26","author":"PM Camacho","year":"2020","unstructured":"Camacho PM, Petak SM, Binkley N, Diab DL, Eldeiry LS, Farooki A, et al. American Association of Clinical Endocrinologists\/American College of Endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis \u2014 2020 update. Endocr Pract. 2020;26(Suppl 1):1\u201346. https:\/\/doi.org\/10.4158\/GL-2020-0524SUPPL.","journal-title":"Endocr Pract"},{"issue":"5","key":"967_CR6","doi-asserted-by":"publisher","first-page":"707","DOI":"10.20945\/2359-3997000000566","volume":"66","author":"L Bandeira","year":"2022","unstructured":"Bandeira L, Lewiecki EM. Anabolic therapy for osteoporosis: update on efficacy and safety. Arch Endocrinol Metab. 2022;66(5):707\u201316. https:\/\/doi.org\/10.20945\/2359-3997000000566.","journal-title":"Arch Endocrinol Metab"},{"issue":"2","key":"967_CR7","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1002\/jbm4.10041","volume":"2","author":"BZ Leder","year":"2018","unstructured":"Leder BZ. Optimizing sequential and combined anabolic and antiresorptive osteoporosis therapy. JBMR Plus. 2018;2(2):62\u20138. https:\/\/doi.org\/10.1002\/jbm4.10041.","journal-title":"JBMR Plus"},{"issue":"10102","key":"967_CR8","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1016\/S0140-6736(17)31613-6","volume":"390","author":"BL Langdahl","year":"2017","unstructured":"Langdahl BL, Libanati C, Crittenden DB, Bolognese MA, Brown JP, Daizadeh NS, et al. Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial. Lancet. 2017;390(10102):1585\u201394. https:\/\/doi.org\/10.1016\/S0140-6736(17)31613-6.","journal-title":"Lancet"},{"issue":"7","key":"967_CR9","doi-asserted-by":"publisher","first-page":"467","DOI":"10.7326\/M18-0850","volume":"169","author":"AC Tricco","year":"2018","unstructured":"Tricco AC, Lillie E, Zarin W, O\u2019Brien KK, Colquhoun H, Levac D, et al. PRISMA Extension for Scoping Reviews (PRISMA-ScR): checklist and explanation. Ann Intern Med. 2018;169(7):467\u201373. https:\/\/doi.org\/10.7326\/M18-0850.","journal-title":"Ann Intern Med"},{"issue":"1","key":"967_CR10","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/s11739-018-1874-2","volume":"14","author":"R Nuti","year":"2019","unstructured":"Nuti R, Brandi ML, Checchia G, Di Munno O, Dominguez L, Falaschi P, et al. Guidelines for the management of osteoporosis and fragility fractures. Intern Emerg Med. 2019;14(1):85\u2013102. https:\/\/doi.org\/10.1007\/s11739-018-1874-2.","journal-title":"Intern Emerg Med"},{"issue":"5","key":"967_CR11","doi-asserted-by":"publisher","first-page":"724","DOI":"10.20945\/2359-3997000000564","volume":"66","author":"M Chandran","year":"2022","unstructured":"Chandran M. The why and how of sequential and combination therapy in osteoporosis. A review of the current evidence. Arch Endocrinol Metab. 2022;66(5):724\u201338. https:\/\/doi.org\/10.20945\/2359-3997000000564.","journal-title":"Arch Endocrinol Metab"},{"issue":"1","key":"967_CR12","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1186\/s13018-025-06040-3","volume":"20","author":"P Su","year":"2025","unstructured":"Su P, Li M, Xiao J, Bai L. Effectiveness of anabolic and anti-resorptive agents for preventing postmenopausal osteoporosis fractures: a systematic review and network meta-analysis. J Orthop Surg Res. 2025;20(1):645. https:\/\/doi.org\/10.1186\/s13018-025-06040-3.","journal-title":"J Orthop Surg Res"},{"issue":"2","key":"967_CR13","doi-asserted-by":"publisher","first-page":"673","DOI":"10.3390\/jcm15020673","volume":"15","author":"M Bonifacio","year":"2026","unstructured":"Bonifacio M, Ruggiero M, Lucchetti L, Musorrofiti MG, La Cava G, Chiappetta A, et al. The efficacy and safety of abaloparatide in osteoporosis: a systematic review and meta-analysis. J Clin Med. 2026;15(2):673. https:\/\/doi.org\/10.3390\/jcm15020673.","journal-title":"J Clin Med"},{"key":"967_CR14","unstructured":"Tsuang FY. Effects of cycle therapy vs sequential therapy with romosozumab and denosumab in postmenopausal osteoporosis patients. ClinicalTrials gov 2025:NCT06938152. https:\/\/clinicaltrials.gov\/study\/NCT06938152"},{"issue":"9","key":"967_CR15","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1093\/jbmr\/zjae116","volume":"39","author":"F Cosman","year":"2024","unstructured":"Cosman F, Oates M, Betah D, Timoshanko J, Wang Z, Ferrari S, et al. Romosozumab followed by denosumab versus denosumab only: a post hoc analysis of FRAME and FRAME extension. J Bone Min Res. 2024;39(9):1268\u201377. https:\/\/doi.org\/10.1093\/jbmr\/zjae116.","journal-title":"J Bone Min Res"},{"issue":"6","key":"967_CR16","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1093\/jbmr\/zjaf053","volume":"40","author":"F Cosman","year":"2025","unstructured":"Cosman F, Mitlak BH, Wang Y, Pearman L, Moreira CA, Lewiecki EM, et al. Probability of achieving bone mineral density treatment targets with abaloparatide and teriparatide. J Bone Min Res. 2025;40(6):773\u20138. https:\/\/doi.org\/10.1093\/jbmr\/zjaf053.","journal-title":"J Bone Min Res"},{"issue":"9999","key":"967_CR17","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1016\/S0140-6736(15)61120-5","volume":"386","author":"BZ Leder","year":"2015","unstructured":"Leder BZ, Tsai JN, Uihlein AV, Wallace PM, Lee H, Neer RM, et al. Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial. Lancet. 2015;386(9999):1147\u201355. https:\/\/doi.org\/10.1016\/S0140-6736(15)61120-5.","journal-title":"Lancet"},{"key":"967_CR18","doi-asserted-by":"publisher","first-page":"e068033","DOI":"10.1136\/bmj-2021-068033","volume":"381","author":"MN H\u00e4ndel","year":"2023","unstructured":"H\u00e4ndel MN, Cardoso I, von B\u00fclow C, Rohde JF, Ussing A, Nielsen SM, et al. Fracture risk reduction and safety by osteoporosis treatment compared with placebo or active comparator in postmenopausal women: systematic review, network meta-analysis, and meta-regression analysis of randomised clinical trials. BMJ. 2023;381:e068033. https:\/\/doi.org\/10.1136\/bmj-2021-068033.","journal-title":"BMJ"},{"issue":"15","key":"967_CR19","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1056\/NEJMoa1708322","volume":"377","author":"KG Saag","year":"2017","unstructured":"Saag KG, Petersen J, Brandi ML, Karaplis AC, Lorentzon M, Thomas T, et al. Romosozumab or alendronate for fracture prevention in women with osteoporosis. N Engl J Med. 2017;377(15):1417\u201327. https:\/\/doi.org\/10.1056\/NEJMoa1708322.","journal-title":"N Engl J Med"},{"key":"967_CR20","unstructured":"Fragility fractures. International Osteoporosis Foundation (health professionals page). https:\/\/www.osteoporosis.foundation\/health-professionals\/fragility-fractures"},{"issue":"2","key":"967_CR21","doi-asserted-by":"publisher","first-page":"416","DOI":"10.14245\/ns.2347256.628","volume":"21","author":"I Jeon","year":"2024","unstructured":"Jeon I, Park SB, Moon BJ, Choi M, Kuh SU, Kim J. Comparison of the clinical efficacy of anabolic agents and bisphosphonates in the patients with osteoporotic vertebral fracture: systematic review and meta-analysis of randomized controlled trials. Neurospine. 2024;21(2):416\u201329. https:\/\/doi.org\/10.14245\/ns.2347256.628.","journal-title":"Neurospine"},{"issue":"2","key":"967_CR22","doi-asserted-by":"publisher","first-page":"430","DOI":"10.14245\/ns.2448592.296","volume":"21","author":"DC Cho","year":"2024","unstructured":"Cho DC. Commentary on \u2018Comparison of the clinical efficacy of anabolic agents and bisphosphonates in the patients with osteoporotic vertebral fracture: systematic review and meta-analysis of randomized controlled trials\u2019. Neurospine. 2024;21(2):430\u20131. https:\/\/doi.org\/10.14245\/ns.2448592.296.","journal-title":"Neurospine"},{"issue":"9","key":"967_CR23","doi-asserted-by":"publisher","first-page":"M498","DOI":"10.1093\/gerona\/55.9.M498","volume":"55","author":"J Magaziner","year":"2000","unstructured":"Magaziner J, Hawkes W, Hebel JR, Zimmerman SI, Fox KM, Dolan M, et al. Recovery from hip fracture in eight areas of function. J Gerontol Biol Sci Med Sci. 2000;55(9):M498\u2013507. https:\/\/doi.org\/10.1093\/gerona\/55.9.M498.","journal-title":"J Gerontol Biol Sci Med Sci"},{"issue":"1","key":"967_CR24","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1186\/s13018-025-06084-5","volume":"20","author":"JY Park","year":"2025","unstructured":"Park JY, Lim JY, Kim TK, Cho BW, Kwon HM, Park KK, et al. Short-term anabolic agent and sequential therapy to improve bone mineral density and bone turnover markers in patients with osteoporotic hip fractures. J Orthop Surg Res. 2025;20(1):662. https:\/\/doi.org\/10.1186\/s13018-025-06084-5.","journal-title":"J Orthop Surg Res"},{"issue":"3 Suppl","key":"967_CR25","doi-asserted-by":"publisher","first-page":"S61","DOI":"10.1177\/21925682241289899","volume":"15","author":"Z Sardar","year":"2025","unstructured":"Sardar Z, Coury J, Polly D, Cheung K, Lewis SJ. Osteoporosis in adult patients undergoing spinal reconstructive surgery: associated complications and management. Global Spine J. 2025;15(3 Suppl):S61\u201374. https:\/\/doi.org\/10.1177\/21925682241289899.","journal-title":"Global Spine J"},{"key":"967_CR26","doi-asserted-by":"publisher","first-page":"1566890","DOI":"10.3389\/fphar.2025.1566890","volume":"16","author":"ZH Zhao","year":"2025","unstructured":"Zhao ZH, Ling T, Ye S, Luo W, Ma JX, Ma X. Effectiveness of treatments to prevent femoral periprosthetic bone loss following total hip arthroplasty: a network meta-analysis. Front Pharmacol. 2025;16:1566890. https:\/\/doi.org\/10.3389\/fphar.2025.1566890.","journal-title":"Front Pharmacol"},{"issue":"4","key":"967_CR27","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1038\/s41584-024-01094-9","volume":"20","author":"NR Fuggle","year":"2024","unstructured":"Fuggle NR, Beaudart C, Bruy\u00e8re O, Abrahamsen B, Al-Daghri N, Burlet N, et al. Evidence-based guideline for the management of osteoporosis in men. Nat Rev Rheumatol. 2024;20(4):241\u201351. https:\/\/doi.org\/10.1038\/s41584-024-01094-9.","journal-title":"Nat Rev Rheumatol"},{"key":"967_CR28","doi-asserted-by":"publisher","first-page":"753185","DOI":"10.3389\/fendo.2021.753185","volume":"12","author":"Y Hirooka","year":"2021","unstructured":"Hirooka Y, Nozaki Y, Okuda S, Sugiyama M, Kinoshita K, Funauchi M, et al. Four-year teriparatide followed by denosumab vs continuous denosumab in glucocorticoid-induced osteoporosis patients with prior bisphosphonate treatment. Front Endocrinol (Lausanne). 2021;12:753185. https:\/\/doi.org\/10.3389\/fendo.2021.753185.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"4","key":"967_CR29","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1007\/s00198-022-06626-1","volume":"34","author":"G Yu","year":"2023","unstructured":"Yu G, Tong S, Liu J, Wan Y, Wan M, Li S, et al. A systematic review of cost-effectiveness analyses of sequential treatment for osteoporosis. Osteoporos Int. 2023;34(4):641\u201358. https:\/\/doi.org\/10.1007\/s00198-022-06626-1.","journal-title":"Osteoporos Int"},{"issue":"7","key":"967_CR30","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1007\/s40273-023-01270-x","volume":"41","author":"M Hiligsmann","year":"2023","unstructured":"Hiligsmann M, Silverman SS, Singer AJ, Pearman L, Mathew J, Wang Y, et al. Cost-effectiveness of sequential abaloparatide\/alendronate in men at high risk of fractures in the United States. PharmacoEconomics. 2023;41(7):819\u201330. https:\/\/doi.org\/10.1007\/s40273-023-01270-x.","journal-title":"PharmacoEconomics"},{"issue":"1","key":"967_CR31","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1210\/clinem\/dgaa756","volume":"106","author":"E Tsourdi","year":"2021","unstructured":"Tsourdi E, Zillikens MC, Meier C, Body JJ, Gonzalez Rodriguez E, Anastasilakis AD, et al. Fracture risk and management of discontinuation of denosumab therapy: a systematic review and position statement by ECTS. J Clin Endocrinol Metab. 2021;106(1):264\u201381. https:\/\/doi.org\/10.1210\/clinem\/dgaa756.","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"967_CR32","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1002\/jbmr.3337","volume":"33","author":"SR Cummings","year":"2018","unstructured":"Cummings SR, Ferrari S, Eastell R, Gilchrist N, Jensen JB, McClung M, et al. Vertebral fractures after discontinuation of denosumab: a post hoc analysis of the randomized placebo-controlled FREEDOM trial and its extension. J Bone Min Res. 2018;33(2):190\u20138. https:\/\/doi.org\/10.1002\/jbmr.3337.","journal-title":"J Bone Min Res"},{"key":"967_CR33","doi-asserted-by":"publisher","unstructured":"Kamanda-Kosseh M, Shiau S, Agarwal S, Kondapalli A, Colon I, Kil N, et al. Bisphosphonates maintain BMD after sequential teriparatide and denosumab in premenopausal women with idiopathic osteoporosis. J Clin Endocrinol Metab. 2024;110(3). https:\/\/doi.org\/10.1210\/clinem\/dgae240.","DOI":"10.1210\/clinem\/dgae240"},{"issue":"10","key":"967_CR34","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1093\/jbmr\/zjae119","volume":"39","author":"F Cosman","year":"2024","unstructured":"Cosman F, Lewiecki EM, Eastell R, Ebeling PR, Jan de Beur S, Langdahl B, et al. Goal-directed osteoporosis treatment: a progress report from the ASBMR\/BHOF Task Force. J Bone Min Res. 2024;39(10):1393\u2013405. https:\/\/doi.org\/10.1093\/jbmr\/zjae119.","journal-title":"J Bone Min Res"},{"key":"967_CR35","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1097\/BLO.0b013e3180534269","volume":"461","author":"BJ Edwards","year":"2007","unstructured":"Edwards BJ, Bunta AD, Simonelli C, Bolander M, Fitzpatrick LA. Prior fractures are common in patients with subsequent hip fractures. Clin Orthop Relat Res. 2007;461:226\u201330. https:\/\/doi.org\/10.1097\/BLO.0b013e3180534269.","journal-title":"Clin Orthop Relat Res"},{"issue":"1","key":"967_CR36","doi-asserted-by":"publisher","first-page":"32","DOI":"10.23785\/TU.2025.01.007","volume":"82","author":"C Meier","year":"2025","unstructured":"Meier C, Everts J -Graber, Ferrari S. Osteoporose-Therapie Update 2025, Teil 2: Sequenzielle Therapie der Osteoporose [Update 2025, Part 2: Sequential osteoporosis therapy]. Ther Umsch. 2025;82(1):32\u20134. https:\/\/doi.org\/10.23785\/TU.2025.01.007.","journal-title":"Ther Umsch"},{"issue":"8","key":"967_CR37","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1056\/NEJMoa0809493","volume":"361","author":"SR Cummings","year":"2009","unstructured":"Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R, Reid IR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med. 2009;361(8):756\u201365. https:\/\/doi.org\/10.1056\/NEJMoa0809493.","journal-title":"N Engl J Med"}],"container-title":["Current Osteoporosis Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11914-026-00967-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11914-026-00967-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11914-026-00967-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T03:11:10Z","timestamp":1777950670000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11914-026-00967-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,5]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["967"],"URL":"https:\/\/doi.org\/10.1007\/s11914-026-00967-0","relation":{},"ISSN":["1544-2241"],"issn-type":[{"value":"1544-2241","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,5]]},"assertion":[{"value":"10 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Institutional Review Board Statement"}},{"value":"Waived.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed Consent Statement"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}},{"value":"The authors declare no conflict of interest.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}],"article-number":"19"}}